Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Autor: W, Lark M, B, Stroup G, M, Hwang S, E, James I, J, Rieman D, H, Drake F, N, Bradbeer J, A, Mathur, F, Erhard K, A, Newlander K, T, Ross S, L, Salyers K, R, Smith B, H, Miller W, F, Huffman W, M, Gowen

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; November 1999, Vol. 291 Issue: 2 p612-7, 6p